Dyne Therapeutics, Inc. Financials
This page shows Dyne Therapeutics, Inc. (DYN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Dyne Therapeutics, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Dyne Therapeutics, Inc. generates $0.92 in operating cash flow (-$292.4M OCF vs -$317.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Dyne Therapeutics, Inc.'s EBITDA was -$342.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 42.3% from the prior year.
Dyne Therapeutics, Inc. generated -$294.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 56.0% from the prior year.
Dyne Therapeutics, Inc. reported -$317.4M in net income in fiscal year 2024. This represents a decrease of 34.5% from the prior year.
Dyne Therapeutics, Inc. earned $-3.37 per diluted share (EPS) in fiscal year 2024. This represents an increase of 14.7% from the prior year.
Dyne Therapeutics, Inc. held $435.4M in cash against $0 in long-term debt as of fiscal year 2024.
Dyne Therapeutics, Inc. had 102M shares outstanding in fiscal year 2024. This represents an increase of 66.5% from the prior year.
Dyne Therapeutics, Inc. invested $281.4M in research and development in fiscal year 2024. This represents an increase of 33.5% from the prior year.
Dyne Therapeutics, Inc. invested $2.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 225.9% from the prior year.
DYN Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $97.2M+4.8% | $92.8M | N/A | $55.3M | N/A | $34.7M | N/A | $36.5M |
| SG&A Expenses | $16.7M+29.7% | $12.9M | N/A | $7.0M | N/A | $7.6M | N/A | $6.3M |
| Operating Income | -$113.9M-7.9% | -$105.6M | N/A | -$62.3M | N/A | -$42.3M | N/A | -$42.8M |
| Interest Expense | $2.9M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$108.0M-11.2% | -$97.1M | N/A | -$60.2M | N/A | -$41.4M | N/A | -$42.6M |
| EPS (Diluted) | $-0.76+20.8% | $-0.96 | N/A | $-0.99 | N/A | $-0.80 | N/A | $-0.83 |
DYN Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $867.1M+25.4% | $691.2M+318.7% | $165.1M-19.6% | $205.2M-33.0% | $306.3M+2.2% | $299.7M-29.6% | $425.7M-8.8% | $466.9M |
| Current Assets | $806.3M+22.3% | $659.3M+409.6% | $129.4M-23.1% | $168.2M-36.7% | $265.6M+2.9% | $258.2M-32.5% | $382.4M-10.0% | $424.7M |
| Cash & Equivalents | $573.6M+31.7% | $435.4M+258.0% | $121.6M-6.6% | $130.3M-24.3% | $172.1M+18.8% | $144.9M-27.8% | $200.8M-12.3% | $229.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $175.3M+185.5% | $61.4M-16.8% | $73.8M+38.7% | $53.2M-1.4% | $54.0M+8.1% | $49.9M-13.1% | $57.5M+8.9% | $52.8M |
| Current Liabilities | $59.8M+41.6% | $42.3M-17.3% | $51.1M+72.1% | $29.7M+5.7% | $28.1M+20.4% | $23.3M-18.8% | $28.7M+23.0% | $23.4M |
| Long-Term Debt | $99.1M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $691.8M+9.8% | $629.8M+589.9% | $91.3M-40.0% | $152.0M-39.8% | $252.4M+1.0% | $249.7M-32.2% | $368.2M-11.1% | $414.1M |
| Retained Earnings | -$1.3B-35.2% | -$949.9M-50.2% | -$632.5M-11.8% | -$565.9M-42.7% | -$396.6M-10.9% | -$357.7M-56.6% | -$228.5M-29.3% | -$176.7M |
DYN Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$90.8M-7.6% | -$84.3M-140.9% | -$35.0M+30.8% | -$50.6M-73.3% | -$29.2M+31.8% | -$42.8M-52.5% | -$28.1M-4.1% | -$27.0M |
| Capital Expenditures | $395K-63.3% | $1.1M+1211.0% | $82K-50.9% | $167K-67.8% | $519K-41.4% | $886K-55.5% | $2.0M+125.9% | $881K |
| Free Cash Flow | -$91.2M-6.7% | -$85.4M-143.4% | -$35.1M+30.9% | -$50.8M-70.9% | -$29.7M+32.0% | -$43.7M-45.4% | -$30.1M-8.0% | -$27.8M |
| Investing Cash Flow | -$38.0M-137.1% | -$16.0M-161.1% | $26.2M+104.3% | $12.8M-33.4% | $19.2M-62.8% | $51.7M+22082.1% | -$235K+91.7% | -$2.8M |
| Financing Cash Flow | $217.3M+5877.1% | $3.6M+2373.5% | $147K-67.6% | $454K-98.8% | $37.2M+53047.1% | $70K-21.3% | $89K-80.5% | $457K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DYN Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.5%+0.2pp | -12.6% | N/A | -29.3% | N/A | -13.8% | N/A | -9.1% |
| Current Ratio | 13.47-2.1 | 15.60+13.1 | 2.53-3.1 | 5.67-3.8 | 9.46-1.6 | 11.07-2.2 | 13.31-4.9 | 18.19 |
| Debt-to-Equity | 0.14+0.1 | 0.00-0.8 | 0.81+0.5 | 0.35+0.1 | 0.21+0.0 | 0.20+0.0 | 0.16+0.0 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Dyne Therapeutics, Inc. profitable?
No, Dyne Therapeutics, Inc. (DYN) reported a net income of -$317.4M in fiscal year 2024.
What is Dyne Therapeutics, Inc.'s earnings per share (EPS)?
Dyne Therapeutics, Inc. (DYN) reported diluted earnings per share of $-3.37 for fiscal year 2024. This represents a 14.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Dyne Therapeutics, Inc.'s EBITDA?
Dyne Therapeutics, Inc. (DYN) had EBITDA of -$342.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Dyne Therapeutics, Inc. have?
As of fiscal year 2024, Dyne Therapeutics, Inc. (DYN) had $435.4M in cash and equivalents against $0 in long-term debt.
What is Dyne Therapeutics, Inc.'s free cash flow?
Dyne Therapeutics, Inc. (DYN) generated -$294.7M in free cash flow during fiscal year 2024. This represents a -56.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Dyne Therapeutics, Inc.'s operating cash flow?
Dyne Therapeutics, Inc. (DYN) generated -$292.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Dyne Therapeutics, Inc.'s total assets?
Dyne Therapeutics, Inc. (DYN) had $691.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Dyne Therapeutics, Inc.'s capital expenditures?
Dyne Therapeutics, Inc. (DYN) invested $2.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Dyne Therapeutics, Inc. spend on research and development?
Dyne Therapeutics, Inc. (DYN) invested $281.4M in research and development during fiscal year 2024.
How many shares does Dyne Therapeutics, Inc. have outstanding?
Dyne Therapeutics, Inc. (DYN) had 102M shares outstanding as of fiscal year 2024.
What is Dyne Therapeutics, Inc.'s current ratio?
Dyne Therapeutics, Inc. (DYN) had a current ratio of 15.60 as of fiscal year 2024, which is generally considered healthy.
What is Dyne Therapeutics, Inc.'s debt-to-equity ratio?
Dyne Therapeutics, Inc. (DYN) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dyne Therapeutics, Inc.'s return on assets (ROA)?
Dyne Therapeutics, Inc. (DYN) had a return on assets of -45.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Dyne Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Dyne Therapeutics, Inc. (DYN) had $435.4M in cash against an annual operating cash burn of $292.4M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Dyne Therapeutics, Inc.'s Piotroski F-Score?
Dyne Therapeutics, Inc. (DYN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dyne Therapeutics, Inc.'s earnings high quality?
Dyne Therapeutics, Inc. (DYN) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.